GLP-1 receptor agonists: Strategic market shift

Tern plc

GLP-1 receptor agonists have moved rapidly from a niche diabetes therapy to a central pillar of metabolic treatment. For investors, this is no longer simply a clinical story. It is a structural shift in how obesity and related conditions are managed, funded and regulated.

Originally introduced to improve glycaemic control in type 2 diabetes, GLP-1RAs have gained prominence through demonstrated weight loss benefits during active treatment. That expansion has materially widened the addressable market. Demand has accelerated across both specialist and primary care settings, prompting regulators and health systems to respond with clearer prescribing frameworks and guidance on appropriate use.

The investment relevance lies in sustainability. While weight reduction during therapy has been consistent, outcomes following treatment discontinuation vary. Evidence suggests that weight regain can occur when therapy stops, raising questions around duration of treatment, reimbursement models and long-term adherence. This dynamic directly affects revenue visibility and pricing strategy. A therapy that requires extended use supports recurring revenue models but also invites payer scrutiny over cost-effectiveness.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search